Verrica CEO to Present at H.C. Wainwright Conference

Event summary

Verrica Pharmaceuticals CEO Jayson Rieger to present at H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026.
YCANTH® (VP-102) approved for molluscum contagiosum, with development ongoing for common warts.
Verrica licensed VP-315 (ruxotemitide) from Lytix Biopharma for non-melanoma skin cancers.
Live webcast available via Verrica's website, replay accessible for 90 days post-event.

The big picture

Verrica Pharmaceuticals is positioning itself as a key player in dermatological treatments, with a focus on both infectious skin conditions and skin cancers. The company’s participation in the H.C. Wainwright conference underscores its efforts to engage investors as it advances its pipeline. The strategic licensing of VP-315 from Lytix Biopharma further solidifies its commitment to expanding its portfolio in the dermatology space.

What we're watching

Pipeline Progress: How the development of VP-315 for non-melanoma skin cancers will impact Verrica’s market position.
Commercialization Strategy: Whether Verrica can successfully expand YCANTH’s use to common warts, addressing a significant unmet need.
Investor Sentiment: The reception of Verrica’s strategic updates at the H.C. Wainwright conference and its potential effect on stock performance.